Introducing our new branding as Rare Compute. Rare Compute is a biotechnology company focused on AI and providing GPUs to accelerate research and cures for rare diseases!

Hey Chicago! Mark your calendars. Our co-founder @ayatabourashed is breaking down how DeSci and Poscidon are changing the future of science. 📅 Nov 21 | 6:30–9:00 PM 🎟 RSVP:

@prmshra @rarecompute will play a pivotal role in drug discovery

Scientists don’t fail. The funding system fails them. At Poscidon, we’re building a new way to fund discovery: transparent, community-led, and unstoppable.

What is compute, and why does it matter for rare disease research? In science, compute refers to the processing power that allows us to run complex models, analyze large datasets, and simulate biology in detail. Think of it as the engine that turns raw data into scientific

DeSci doesn’t care if your lab is at Harvard or your garage. If the science is solid, the community funds it. That’s how innovation starts.

Why care about rare diseases? Because they are often the first place new biology shows itself. A single mutation in one patient can uncover an unknown protein function, a pathway with no precedent, or a molecular mechanism that reshapes how we understand health and disease.

🧬 Model Spotlight: gLM2 gLM2 is a new kind of protein language model. It learns not just from protein sequences but from genomic context, using DNA collected from diverse ecosystems. Instead of curated lab databases, gLM2 was trained on real-world metagenomic data. That means

If you are an ambitious graduate student studying molecular engineering and/or bioinformatics and are looking for an internship then we want to talk to you

What’s the difference between a wet lab and a dry lab—and why does it matter? A wet lab is where biology meets the physical world. Scientists work with molecules, DNA, cells, and organisms to run real-world experiments and observe how biology behaves under specific conditions.

Why work in rare disease? Because this is where breakthroughs start. As Dr. Gareth Baynam shares, innovation here doesn’t stay in a silo—it drives progress across medicine and technology. At Rare Compute, we believe AI can help speed up that impact. – Featuring our friend Dr.

Researchers have developed a #DeepLearning system called BioEmu that rapidly generates diverse protein conformations, enabling fast, accurate insights into protein flexibility and function. Learn more this week in Science: https://t.co/Pe15hm9F52

Decentralized science (DeSci) is a movement to make research more open, collaborative, and community-driven. Instead of relying on a few institutions to fund and direct science, DeSci uses blockchain tools to let communities coordinate funding, share data openly, and reward

It’s not a typo. It’s Poscidon. And we’re making waves in science. 🌊

🧬 Autoimmune diseases are accelerating, and current systems are not equipped to respond. Hundreds of millions of people are affected worldwide, and some studies show incidence and prevalence rising by 12 to 19 percent each year. Diagnosis is often slow, with many patients

The single biggest barrier in rare disease? Awareness. It’s time to change that.

TradSci: Apply. Wait. Hope. DeSci: Propose. Vote. Build.

DAOs Work! 🧪💰🧬💸 @PoSciDonDAO has been quietly funding science: first granting $115K USDC to @rarecompute for AI-driven rare disease discovery - and then $70K USD to Nephronet for AI-powered early kidney disease detection. Imaging being a scientist and having the

“There is a fundamental moral driver and an economic imperative to care more about rare diseases.” - Dr. Gareth Baynam. Rare disease isn’t rare when you look closer. Beyond the moral responsibility, the economic costs are enormous, and action can’t wait. Join us in driving

This is the most detailed model of a human cell ever created, built using real scientific data from X-ray crystallography, NMR, and cryo-electron microscopy. Titled “Cellular landscape cross-section through a eukaryotic cell,” this stunning visualization by Evan Ingersoll and

Gareth says it best: “Why wouldn’t you work in rare disease?” A while back, we sat down with Dr. Gareth Baynam to talk about his journey in rare disease research, the humanity that drives his work, and why this field demands more attention and innovation. Though individually